Invasive Candida species infection:: the importance of adequate empirical antifungal therapy

被引:24
作者
Armstrong-James, Darius [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Mol Microbiol & Infect, London SW7 2AZ, England
关键词
antifungal therapy; candidiasis; clinical mycology;
D O I
10.1093/jac/dkm260
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Candida species are a common cause of bloodstream and invasive infection in critically ill and immunosuppressed patients. Furthermore, invasive Candida infection carries a poor prognosis and may initially be mistaken for bacterial infection. An article in this issue of the Journal investigates the relationship between adequacy of initial empirical therapy and outcome from invasive Candida infection. This study shows that adequate empirical therapy is received by only a quarter of patients, and that inappropriate therapy is associated with increased mortality. These findings highlight the importance of appropriate empirical therapy in invasive Candida infection.
引用
收藏
页码:459 / 460
页数:2
相关论文
共 17 条
[1]   In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].
Barry, AL ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949
[2]   Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956
[3]   In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest [J].
Fleck, Ralf ;
Dietz, Annebaerbel ;
Hof, Herbert .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (04) :767-771
[4]  
GARDINER G, 2007, CLIN MICROBIOL INFEC, V13, pS351
[5]  
*HLTH PROT AG, FUNG DIS UK CURR PRO
[6]   Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial [J].
Kullberg, BJ ;
Sobel, JD ;
Ruhnke, M ;
Pappas, PG ;
Viscoli, C ;
Rex, JH ;
Cleary, JD ;
Rubinstein, E ;
Church, LWP ;
Brown, JM ;
Schlamm, HT ;
Oborska, IT ;
Hilton, F ;
Hodges, MR .
LANCET, 2005, 366 (9495) :1435-1442
[7]   Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial [J].
Kuse, Ernst-Ruediger ;
Chetchotisakd, Ploenchan ;
da Cunha, Clovis Arns ;
Ruhnke, Markus ;
Barrios, Carlos ;
Raghunadharao, Digumarti ;
Sekhon, Jagdev Singh ;
Freire, Antonio ;
Ramasubramanian, Venkatasubramanian ;
Demeyer, Ignace ;
Nucci, Marcio ;
Leelarasamee, Amorn ;
Jacobs, Frederique ;
Decruyenaere, Johan ;
Pittet, Didier ;
Ullmann, Andrew J. ;
Ostrosky-Zeichner, Luis ;
Lortholary, Olivier ;
Koblinger, Sonja ;
Diekmann-Berndt, Heike ;
Cornely, Oliver A. .
LANCET, 2007, 369 (9572) :1519-1527
[8]   Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality [J].
Morrell, M ;
Fraser, VJ ;
Kollef, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3640-3645
[9]   β-D-glucan as a diagnostic adjunct for invasive fungal infections:: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome [J].
Odabasi, Z ;
Mattiuzzi, G ;
Estey, E ;
Kantarjian, H ;
Saeki, F ;
Ridge, RJ ;
Ketchum, PA ;
Finkelman, MA ;
Rex, JH ;
Ostrosky-Zeichner, L .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (02) :199-205
[10]   Guidelines for treatment of candidiasis [J].
Pappas, PG ;
Rex, JH ;
Sobel, JD ;
Filler, SG ;
Dismukes, WE ;
Walsh, TJ ;
Edwards, JE .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) :161-189